Bayer Issues Additional Guidance to Physicians on Trasylol®
Bayer announced new guidance to physicians and health care providers regarding the use of Trasylol® (aprotinin injection) in patients at an increased risk of blood loss and blood transfusion undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).
Read more ...
One-Year Results from the Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Abbott (NYSE: ABT) announced continued positive results from ABSORB, the world's first clinical trial evaluating the safety and performance of a fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease.
Read more ...
Abbott Named to Science Magazine's List of Top Employers
For the fifth consecutive year, Abbott (NYSE: ABT) has been named among the top 20 employers in the Science magazine 2007 Top Biotech and Pharma Employer's survey.
Read more ...
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent
Pfizer Inc said that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The calcium salt patent expires in July 2010.
Read more ...
Novartis delivers record earnings in first nine months of 2007
Strong operational performance for Group continuing operations:
Nine-month net sales up 13% to USD 28.1 billion (+9% local currencies) driven by all divisions, particularly Vaccines and Diagnostics and Sandoz
Operating income rises 9% to USD 6.5 billion, excluding a one-time incremental environmental provision of USD 590 million to cover worldwide remediation plans
Strong sales growth in the first nine months of 2007
Group sales up 12% in local currencies to 33.9 billion Swiss francs. As anticipated, Tamiflu sales decline significantly in third quarter following completion of outstanding pandemic stockpiling orders. Full-year outlook reaffirmed: Group and Pharmaceuticals Division anticipate double-digit sales increases, and both divisions expect above-market growth; target is for Core Earnings per Share to grow faster than Group sales.
Read more ...
Pfizer Reports Third-Quarter 2007 Results
Third-Quarter 2007 Reported Diluted EPS of $0.11 Represents a Decline of 76% Compared to the Same Period Last Year and Includes Charges of $0.31 ($2.8 Billion Pre-Tax) Related to a Decision to Exit Exubera.
Adjusted Diluted EPS of $0.58 for the Third-Quarter 2007 Represents an Increase of 7% Compared to the Same Period a Year Ago.
Read more ...